Home page500124 • BOM
add
Dr. Reddy's Laboratories
Chiusura precedente
1200,50 ₹
Intervallo giornaliero
1188,65 ₹ - 1210,40 ₹
Intervallo annuale
1074,35 ₹ - 1420,20 ₹
Cap di mercato
995,48 Mld INR
Volume medio
58.811,00
Rapporto P/E
18,66
Dividendo/Prezzo
0,67%
Borsa valori principale
NSE
Notizie
Dati finanziari
Conto economico
Entrate
Utile netto
(INR) | set 2024info | Variazione Y/Y |
---|---|---|
Entrate | 80,16 Mld | 16,51% |
Spese di gestione | 29,72 Mld | 24,54% |
Utile netto | 12,55 Mld | -15,18% |
Margine di profitto netto | 15,66 | -27,20% |
Utili per azione | 15,83 | -11,13% |
EBITDA | 22,02 Mld | 8,53% |
Aliquota fiscale effettiva | 30,01% | — |
Stato patrimoniale
Totale attivo
Totale passivo
(INR) | set 2024info | Variazione Y/Y |
---|---|---|
Investimenti cash/breve termine | 63,07 Mld | -7,15% |
Totale attivo | 465,96 Mld | 34,27% |
Totale passivo | 156,67 Mld | 66,79% |
Patrimonio netto totale | 309,28 Mld | — |
Azioni in circolazione | 833,05 Mln | — |
Prezzo/valore contabile | 3,28 | — |
Redditività dell'attivo | 10,24% | — |
Rendimento sul capitale | 13,21% | — |
Flusso di cassa
Flusso di cassa netto
(INR) | set 2024info | Variazione Y/Y |
---|---|---|
Utile netto | 12,55 Mld | -15,18% |
Liquidità di esercizio | 9,32 Mld | -48,03% |
Contanti da investimenti | -19,07 Mld | -322,21% |
Contanti da finanziamenti | 16,15 Mld | 329,53% |
Flusso di cassa netto | 6,37 Mld | 1,03% |
Flusso di cassa libero | 3,92 Mld | -72,47% |
Informazioni
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
CEO
Fondazione
1984
Sito web
Dipendenti
27.048